The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | REBUILD: effect of daratumumab on bone metabolism in R/R myeloma
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece presents the results from a preliminary analysis of the REBUILD study (NCT03475628) of the effect of daratumumab (dara) on bone metabolism in advanced relapsed/refractory (R/R) multiple myeloma, where osteolytic lesions are characteristic. With pre-clinical studies showing that anti-CD38 therapy inhibits osteoclast formation, the Phase II trial aims to evaluate the impact of dara monotherapy, an anti-CD38 monoclonal antibody, on bone resorption markers: C-terminal telopeptide of collagen type I (CTX) and tartrate-resistant acid phosphatase isoform 5b (TRACP-5b). Of the 29 patients with bone marker data available, the median changes in CTX and TRAXP-5b after four months were 3.9% and -2.2%, respectively. Comparing individuals who achieved a response to those who did not, changes were 3% vs 4% for CTX and -3% vs 9% for TRACP-5b. Responders also showed a greater increase in numerous bone formation markers. These initial results show dara has a positive effect on bone metabolism, likely via an osteoclast inhibitory mechanism. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
